INSERM, U925, Université de Picardie Jules Verne, UFR de Médecine, 3 Rue des Louvels, 80036 Amiens, France.
J Biol Chem. 2011 Feb 18;286(7):5034-42. doi: 10.1074/jbc.M110.155903. Epub 2010 Nov 24.
STAT5a and -5b (signal transducers and activators of transcription 5a and 5b) proteins play an essential role in hematopoietic cell proliferation and survival and are frequently constitutively active in hematologic neoplasms and solid tumors. Because STAT5a and STAT5b differ mainly in the carboxyl-terminal transactivation domain, we sought to identify new proteins that bind specifically to this domain by using a bacterial two-hybrid screening. We isolated hTid1, a human DnaJ protein that acts as a tumor suppressor in various solid tumors. hTid1 interacts specifically with STAT5b but not with STAT5a in hematopoietic cell lines. This interaction involves the cysteine-rich region of the hTid1 DnaJ domain. We also demonstrated that hTid1 negatively regulates the expression and transcriptional activity of STAT5b and suppresses the growth of hematopoietic cells transformed by an oncogenic form of STAT5b. Our findings define hTid1 as a novel partner and negative regulator of STAT5b.
STAT5a 和 -5b(信号转导子和转录激活因子 5a 和 5b)蛋白在造血细胞增殖和存活中发挥重要作用,并且在血液肿瘤和实体肿瘤中经常持续活跃。由于 STAT5a 和 STAT5b 主要在羧基末端反式激活结构域上存在差异,我们试图通过细菌双杂交筛选来鉴定专门与该结构域结合的新蛋白。我们分离了 hTid1,这是一种人类 DnaJ 蛋白,在各种实体肿瘤中充当肿瘤抑制因子。hTid1 在造血细胞系中特异性地与 STAT5b 相互作用,但不与 STAT5a 相互作用。这种相互作用涉及 hTid1 DnaJ 结构域的富含半胱氨酸的区域。我们还证明 hTid1 负调控 STAT5b 的表达和转录活性,并抑制由致癌形式的 STAT5b 转化的造血细胞的生长。我们的研究结果将 hTid1 定义为 STAT5b 的新型伴侣和负调节剂。